Latest from Moffitt

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.
Kendra Sweet, MD, sheds light on data regarding treatment discontinuation and how they impact patients with chronic myeloid leukemia.
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.
Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.
Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the impact of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.
Publication Bottom Border
Border Publication
x